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Abstract
Objective
We aimed to determine the association between the stepwise increase in the sustained
viral response (SVR) and Swiss and United States (US) market prices of drug regimens for
treatment-naive, genotype 1 chronic hepatitis C virus (HCV) infection in the last 25 years.
We identified the following five steps in the development of HCV treatment regimens: 1)
interferon (IFN)-αmonotherapy in the early '90s, 2) IFN-α in combination with ribavirin
(RBV), 3) pegylated (peg) IFN-α in combination with RBV, 4) the first direct acting antivirals
(DAAs) (telaprevir and boceprevir) in combination with pegIFN-α and RBV, and 5) newer
DAA-based regimens, such as sofosbuvir (which is or is not combined with ledipasvir) and
fixed-dose combination of ritonavir-boosted paritaprevir and ombitasvir in combination with
dasabuvir.
Design
We performed a linear regression and mean cost analysis to test for an association between
SVRs and HCV regimen prices. We conducted a sensitivity analysis using US prices at the
time of US drug licensing. We selected randomized clinical trials of drugs approved for use
in Switzerland from 1997 to July 2015 including treatment-naïve patients with HCV geno-
type 1 infection.
Results
We identified a statistically significant positive relationship between the proportion of
patients achieving SVRs and the costs of HCV regimens in Switzerland (with a bivariate
ordinary least square regression yielding an R2 measure of 0.96) and the US (R2 = 0.95).
The incremental cost per additional percentage of SVR was 597.14 USD in Switzerland and
1,063.81 USD in the US.
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Conclusion
The pricing of drugs for HCV regimens follows a value-based model, which has a stable
ratio of costs per achieved SVR over 25 years. Health care systems are struggling with the
high resource use of these new agents despite their obvious long-term advantages for the
overall health of the population. Therefore, the pharmaceutical industry, health care payers
and other stakeholders are challenged with finding new drug pricing schemes to treat the
entire population infected with HCV.
Introduction
The development and market approval of novel direct-acting antivirals (DAAs) have dramati-
cally changed the hepatitis C virus (HCV) treatment landscape. For the first time, chronic
HCV infection, a major human pathogen responsible for cirrhosis and hepatocellular carci-
noma and a leading indication for liver transplantation, may be eradicated in all patients using
an all-oral, short-duration, well-tolerated, safe, and highly efficacious treatment.[1]
A new nosological entity first identified in the 1970s, the so-called non-A, non-B hepatitis,
was discovered as HCV in 1989.[2, 3] The first treatment consisted of recombinant interferon
(IFN)-αmonotherapy and was characterized by a low cure percentage (<10%) and severe side
effects.[3] In subsequent decades, new drugs gradually increased the percentage of cure in a
stepwise fashion.[2, 3] The IFN-α in combination with ribavirin (RBV) resulted in 34–42%
cure rates. The substitution of standard IFN-α with its pegylated (peg) form, administered
once per week, resulted in an increase in cure rates from 45% to 80% depending on the HCV
genotype.[4, 5] The first DAAs were telaprevir (TVR) and boceprevir (BOC), which increased
the cure rate up to 70–80% for HCV genotype 1.[6–8] Finally, the arrival of the new DAAs,
such as sofosbuvir (SOF) by itself or in combination with ledipasvir (LDV), and the triple
fixed-dose combination of ritonavir-boosted paritaprevir, ombitasvir (PTV/r/OBV) in combi-
nation with dasabuvir (DSV) led to unprecedented ~100% cure rates in several patient sub-
groups.[9–11] At the same time, two additional DAAs, simeprevir (SMV) and daclatasvir
(DCV), were added to the already available armamentarium.[12–15] However, the new drug
regimens were marketed at very high prices for each treatment compared to their predecessors,
increasing the financial challenge for health care systems aiming to provide the entire HCV-
infected population with access to those medicines. The cost of a 12-week SOF-based regimen
in the United Sates (US) that contains pegIFN-α and RBV exceeded 90,000 USD at registration,
which is much higher than the standard cost of 20,000 USD for historical IFN-αmonotherapy.
[16, 17]
Therefore, a better understanding of the determinants of HCV drug pricing is essential.[18]
Key elements of drug pricing include the amount of money invested in research and develop-
ment (R&D), production costs, efficacy, safety, ease of administration, duration of treatment,
features of treatment comparators, innovation, international benchmarking, market size and
market value.[19–22] Thus, we aimed to determine the potential association between the step-
wise increase in the sustained viral response (SVR) and treatment regimen prices. We assessed
the prices of different regimens at their market entry and the respective SVR rates, which are
listed in the official Swiss label (available at http://www.swissmedicinfo.ch) for treatment-
naive, genotype 1 chronic hepatitis C patients, corresponding to the most prevalent patient
subgroup in our country.[1, 23] We also conducted a sensitivity analysis using US prices at the
time of drug licensing.
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Materials and Methods
Therapy stepping stones
We classified the different treatment regimens into five steps, as suggested by the literature
(Table 1).[3, 24, 25]
We selected all phase 3 randomized clinical trials (RCT) that enrolled previously untreated
patients with chronic HCV genotype 1 infection and tested drugs that were approved by Swiss-
medic, which were therefore marketed in Switzerland from January 1st 1997 to July 31st 2015.
For each of these drugs regimens, we used the SVR rate as reported in the studies at the time of
the Swissmedic marketing authorization request (http://www.swissmedic.org); Swissmedic is
the Swiss agency that authorizes and supervises drugs. The drug price, dosage and duration
were based on the recommended Swissmedic guidelines for HCV treatment-naive patients
with genotype 1 infection during the study period. For older drug regimens that are not listed
in the Swissmedic database, we used data from the corresponding US agency (Food and Drug
Administration, FDA). Finally, because data for IFN-α were not recorded in either database,
we contacted the pharmaceutical companies to determine which published studies contributed
to drug marketing. [4,5] SVR was defined as undetectable HCV RNA in the serum 12 weeks
after the end of treatment for DAA-based regimens and 24 weeks for IFN-α based regimens.
[26]
Swiss market access
In Switzerland, market access is conditional on a two-step decision process. First, a drug must
be approved by Swissmedic.[27] Then, the Federal Office of Public Health (FOPH) decides
whether or not to include the medication in the list of drugs reimbursed by the mandatory
health insurance scheme based on a recommendation by the Federal Drug Commission
(FDC). The FDC evaluates the value of new drugs according to the following three criteria:
effectiveness, appropriateness, and efficiency. Furthermore, the FDC applies reference pricing
using a basket of nine European countries. Finally, the FDC considers the budget impact by
Table 1. Approved drugs for HCV infection in Switzerland and the United States.
Steps Regimen Drugs In combination with
Interferon
Swissmedic
approval
FDA
approval
Step
1
Interferon-α monotherapy IFN-α-2a - 1997
IFN-α-2b - 1998
Step
2
Interferon-α associated with ribavirin RBV Yes 2002 2001
Step
3
Pegylated interferon-α associated with ribavirin pegIFN-α-
2a
2001
pegIFN-α-
2b
- 2003 2002
Step
4
First DAAs (serine protease inhibitors) associated with pegylated
interferon-α and ribavirin
TVR, BOC Yes 2011 2011
SMV Yes 2015 2013
Step
5
Second wave DAAs: nucleotidic and non-nucleosidic polymerase
inhibitors, NS5A inhibitors, more serine protease inhibitors that are or
are not associated with pegylated interferon-α and ribavirin
SOF Yes 2014 2013
SOF/LDV No 2015 2014
PTV/r/OBV
+DSV
No 2014 2015
IFN: interferon; RBV: ribavirin; pegIFN: pegylated interferon; TVR telaprevir; BOC: boceprevir; SMV: simeprevir; SOF: sofosbuvir; LDV: ledipasvir; PTV/r/
OBV: ﬁxed dose combination of ritonavir-boosted paritaprevir and ombitasvir; DSV: dasabuvir
doi:10.1371/journal.pone.0157098.t001
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comparing the total costs of the new treatment regimen with the standard of care. The FOPH
then negotiates the final price with the manufacturer and re-evaluates the drug price every
three years. We performed analysis from a third-party payer perspective.
Cost calculation
The market prices of IFN-α, pegIFN-α and RBV have changed throughout the past 25 years.
Therefore, we controlled for inflation by using the market price of IFN-α for step 1 in 1997,
which was adjusted by the inflation rate for both Swiss and US pricing using an online calcula-
tor (fxtop.com/en/inflation-calculator.php). Likewise, for steps 2 and 3, we used the January
2003 prices of IFN-α, pegIFN-α and RBV, which were adjusted by the inflation rate. For the
first and second wave DAAs included in steps 4 and 5, we used the launching market price and
current price for pegIFN-α and RBV without adjusting for inflation. For the comparison of
prices adjusted to the 2015 level, we considered an exchange rate of one CHF equal to one
USD. Although RBV administration is usually weight-adapted, we arbitrarily considered a
standard daily dose of 1,000 mg for all recipients. We assumed that the US drug costs were
equal to the wholesale acquisition costs (WAC) as listed in the Red Book Online (http://www.
redbook.com/redbook/online). For regimens requiring RBV, and when many manufacturers
shared the RBV market, we selected the cheapest regimen. We also calculated the ratio of costs
per SVR (costs/SVR) for each regimen, representing the costs to cure one patient.
Statistical analysis
We used two methods to assess the HCV therapy pricing model. First, we plotted the costs per
treatment of the twenty-two regimens against the rate of SVR for both Switzerland and the US.
It is noteworthy that ordering according to the SVR rate corresponds to the stepwise increase
in the cure over time described in the literature.[2, 3] Because the scatter diagram indicates a
linear relationship, we tested for the linear correlation between the two variables by the stan-
dard Pearson correlation coefficient and R2 of a bivariate linear regression.[28] Both represent
the overall fit of a linear model. Second, we measured the mean and standard deviation of the
costs and costs per SVR for the five HCV treatment steps.[3, 24] We used Eviews 8 software
(QMS) for the statistical analysis.
Results
Twenty-two RCTs were included in our study, comprising a total of 5,900 patients (Table 2).
Two clinical trials were included for the IFN-αmonotherapy step (n = 476 patients)[4, 29],
two studies for the association between IFN-α and RBV (n = 613 patients)[5, 31], six for step 3
between pegIFN-α and RBV (n = 1,316 patients)[5, 6, 13, 14, 31], six for the first DAAs
(n = 1,992 patients)[6, 7, 13, 14, 32], and six for the newer DAAs (n = 1,503 patients).[9–12, 33]
Table 2 provides the costs and costs per SVR for each individual treatment regimen and
shows a steady cost increase paralleling the increase in the SVR rate for each treatment step.
From step 4 onward, the treatment durations were shortened to 24 or even 12 weeks, and
pegIFN-α could be omitted for most regimens at step 5.
The scatter plot in Fig 1 suggests a positive linear association between SVR and the cost of
HCV treatment regimens using Swiss cost figures. A high degree of positive linear dependence
is indicated by a Pearson correlation coefficient that is close to unity (ρ = 0.98 for Switzerland
and ρ = 0.98 for the US), corresponding to an R2 of 0.96 for Switzerland and 0.95 for the US.
(Note that the two statistical measures are related by the square-root function.) The incremen-
tal costs per additional percentage point of SVR were estimated as 597.14 USD in Switzerland
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Table 2. Treatments, duration, costs and costs per SVR of HCV treatments over time in Switzerland and the US (Table A in S1 File).
Treatment Study Treatment
duration, weeks
Patients, n SVR
achieved/n total
SVR,
%
Swiss
Costs
USD
Costs per SVR in
Switzerland USD
US costs
USD
US costs per
SVR in US
USD
Step 1
IFN-α-2a FDA Roferon
label[29]
48 20/173 11.56% 9,544 82,561 6,148 53,183
IFN-α-2b Reference[4] 48 37/303 12.21% 9,706 79,492 6,046 49,517
Step 2
IFN-α-2b+RBV CARRY
FORWARD[30]
48 111/328 33.84% 23,799 70,328 25,543 75,482
IFN-α-2a+RBV NV15801[31] 48 100/285 35.09% 20,951 59,706 24,584 70,060
Step 3
pegIFN-α-2a
+RBV
ADVANCE[6] 48 158/361 43.77% 34,575 78,992 37,222 85,040
pegIFN-α-2a
+RBV
NV15801[31] 48 132/298 44.30% 34,575 78,047 37,222 84,023
pegIFN-α-2b
+RBV
CARRY
FORWARD[30]
48 58/122 47.54% 33,637 70,755 32,979 69,371
pegIFN-α-2a
+RBV
QUEST-1[13] 48 65/130 50.00% 34,575 69,150 37,222 74,444
pegIFN-α-2a
+RBV
QUEST-2[14] 48 67/134 50.00% 34,575 69,150 37,222 74,444
pegIFN-α-2a
+RBV
NV15942[31] 48 142/271 52.40% 34,575 65,983 37,222 71,034
Step 4
BOC+ pegIFN-
α-2a+RBV
SPRINT-2[7] 4+44 (73%)* 233/368 63.32% 42,566 67,224 57,741 91,189
TVR+ pegIFN-
α-2a+RBV
OPTIMIZE[32] 12+36 (67%)† 270/371 72.78% 47,304 64,996 75,210 103,339
TVR+ pegIFN-
α-2a+RBV
OPTMIZE[32] 12+36 (69%)† 274/369 74.25% 47,091 63,422 74,818 100,765
TVR+ pegIFN-
α-2a+RBV
ADVANCE[6] 12+36 (68%)† 285/363 78.51% 47,240 60,171 75,092 95,646
SMV+ pegIFN-
α+RBV
QUEST-1[13] 12+12 (85%)¶ 210/264 79.55% 44,833 56,358 85,891 107,971
SMV+ pegIFN-
α+RBV
QUEST-2[14] 12+12 (91%)¶ 209/257 81.32% 44,512 54,737 87,741 107,896
Step 5
SOF+ pegIFN-
α-2a+RBV
NEUTRINO[11] 12 262/292 89.73% 62,955 70,160 93,808 104,545
SOF/LDV ION-3[10] 12 208/216 96.30% 62,363 64,759 94,500 98,131
PTV/r/OBV
+DSV+ RBV
SAPHIRE-I[12] 12 455/473 96.19% 63,946 66,479 86,215 89,630
PTV/r/OBV
+DSV+ RBV
PEARL-IV[9] 12 97/100 97.00% 63,946 65,924 86,215 88,881
SOF/LDV ION-1[33] 12 210/213 98.59% 62,363 63,255 94,500 95,852
PTV/r/OBV
+DSV
PEARL-III[9] 12 209/209 100% 61,956 61,956 83,319 83,319
* The stopping rule for response-guided therapy BOC included patients with undetectable HCV RNA from treatment weeks 8 to 24
† A patient qualiﬁed for a shortened TVR therapy duration for HCV RNA <25 IU/ml at weeks 4 and 12.
¶ SMV response-guided therapy involved stopping the treatment after 24 weeks for patients with HCV RNA <25 IU/ml at week 4 (undetectable or
detectable) and <25 IU/ml at week 12 (undetectable)
doi:10.1371/journal.pone.0157098.t002
Drug Pricing Evolution in Hepatitis C
PLOS ONE | DOI:10.1371/journal.pone.0157098 June 16, 2016 5 / 12
and 1,063.81 USD in the US by the slope coefficient of the respective regression model (Tables
B-E in S1 File).
Table 3 details the mean costs and costs per SVR for each new HCV treatment step.
These results confirmed the close association between the mean costs per treatment step
and the mean SVR rate. Fig 2 shows both the individual and the mean costs for each treatment
step, according to the increasing SVR in Switzerland. Finally, Fig 3 shows that the costs per
achieved HCV cure, expressed as the SVR, are relatively stable.
Discussion
Our results show that the costs of drug regimens for treating HCV increased steadily over time,
both in Switzerland and in the US, according to the stepwise approval of new antiviral drugs,
and in close correlation with the corresponding HCV cure rates. This resulted in relatively sta-
ble costs to cure a treatment-naive patient with HCV genotype 1 infection, irrespective of the
fact that drug costs were higher in the US than in Switzerland. Our results are consistent with a
value-based pricing model in which drug costs are closely related to their clinical efficacy. The
relatively stable ratio of costs per achieved SVR, with the exception of the first treatment step,
suggests that the societal willingness to pay for a specific health gain (i.e., one SVR) have
remained relatively stable over time, at least in Switzerland.
For the HCV market, pharmaceutical companies price their drugs based on the value of
SVR and profit maximization rather than the costs of R&D, production, marketing and distri-
bution or the volume of drugs used.[19, 34, 35] These were also the conclusions of a recent
bipartisan US Congress investigation on the SOF drug pricing strategy.[36] Newer antiviral
Fig 1. Scatter plot of costs against SVR of HCV therapies in Switzerland (ρ = 0.98, R2 = 0.96) and the US (ρ =
0.98, R2 = 0.95).
doi:10.1371/journal.pone.0157098.g001
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Table 3. Mean SVR, mean costs, costs per SVR and confidence intervals (CI) of HCV treatments over time in Switzerland and the US (Tables F-J in
S1 File).
Treatment regimens Mean SVR, %
(95% CI)
Mean costs, in
Switzerland, USD (95%
CI)
Mean costs per SVR in
Switzerland, USD (95% CI)
Mean costs in
US, USD (95%
CI)
Mean costs per SVR
in US USD (95% CI)
Step 1: IFN-α monotherapy 11.89%
(5.24%-
18.53%)
9,625 (7,736–11,514) 81,026 (74,128–87,924) 6,097 (-3,580–
15,771)
51,350 (41,406–
61,295)
Step 2: IFN-α and RBV 34.47%
(27.82%-
41.11%)
22,375 (20,486–24,264) 65,017 (58,119–71,915) 25,064 (15,869–
35,217)
72,771 (64,826–
82,715)
Step 3: pegIFN-α and RBV 48.00%
(44.16%-
51.84%)
34,419 (33,328–35,509) 72,013 (68,030–75,996) 36,515 (30,928–
42,102)
76,393 (70,651–
82,134)
Step 4: First DAA protease
inhibitors*, pegIFN-α and
RBV
74.96%
(71.12%-
78.79%)
45,591 (44,500–46,682) 61,151 (57169–65,134) 76,082 (70-495-
81,669)
101,134 (95,393–
106,876)
Step 5: New DAA† ± pegIFN-
α and RBV
96.30%
(92.46%-
1.00%)
62,922 (61,831–64,012) 65,422 (61,440–69,405) 89,760 (84,172–
95,347)
93,393 (87,651–
99,134)
CI: Conﬁdence Interval
* boceprevir; telaprevir; simeprevir
† sofosbuvir; ledipasvir; ritonavir-boosted paritaprevir, ombitasvir, and dasabuvir
doi:10.1371/journal.pone.0157098.t003
Fig 2. Costs associated with the five steps in HCV therapy development over time (SVR steadily increases
with time).
doi:10.1371/journal.pone.0157098.g002
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drugs for HCV infection have significantly benefited from an improved understanding of viral
biology and drug targets in the field of HIV infection.[2] Moreover, and in contrast to biologic
agents in the fields of cancer and immunology, HCV drug production costs are very low.[37]
Drug prices evolved in line with the cure rate from a mere 10% to almost 100% over a
25-year period. Therefore, we could argue that the “very high” nominal prices of the recently
introduced HCV DAAs are justifiable. On the other hand, DAAs have other significant advan-
tages, such as improved safety and tolerability, shorter treatment durations, and entirely oral
administration. These strong advantages–not present at the time of poorly tolerated IFN-α-
based regimens–were not factored into the price of the first DAAs or into the price of the
DAAs for the newer wave. Additionally, the purported innovation conferred by the introduc-
tion of long-awaited, IFN-free regimens was not responsible for boosting the market price.[38]
Some antiviral therapies have not only unprecedented high cure rates but are also safe and
well tolerated, which makes them theoretically useful for treating nearly the entire infected
population, at variance with the IFN-based therapies used in the early 1990s, which were asso-
ciated with many safety issues and therefore of relatively limited use.[24] Also, antiviral thera-
pies potentially prevent the dramatic and costly long-term complications of HCV infection,
such as cirrhosis and hepatocellular carcinoma, loss of productivity and reduced quality of life.
[23, 17] However, nominal drug costs fall short of emphasizing the true financial burden of
large-scale treatment, despite their cost-effectiveness. [39] A number of analyses on novel
HCV treatments have been published, demonstrating that expensive drugs can still be cost-
effective.[1, 16, 40–43] In a recent analysis based on US costs, the incremental cost effectiveness
Fig 3. Cost per SVR associated with SVR rates corresponding to the five steps in the development of HCV
therapies over time (SVR steadily increases with time).
doi:10.1371/journal.pone.0157098.g003
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ratios of DAAs compared to a reference treatment strategy, based on BOC, RBV and pegIFN-
α, varied between 14,432 and 70,097 USD per additional QALY for genotype 1 infection, and
they were highly sensitive to nominal drug prices.[41] For instance, a combination of SOF/
LVD could be cost-saving as long as the weekly cost of SOF was reduced from 7,000 USD to
less than 5,500 USD. Nevertheless, such projections take into account the long-term savings of
curing patients of HCV, while the weight of treatment costs on health systems is immediate.
Additionally, a drug that is considered cost-effective for an individual patient may still be unaf-
fordable for the health care system, which depends on the disease prevalence in the general
population.[44, 45] Thus, the cost-effectiveness of a drug that is measured at the patient level
does not correspond to the cost-affordability of the drug at the population level.[39, 43–45] For
this reason, varying degrees of restrictions have been introduced. In Switzerland, only patients
with advanced fibrosis (Metavir F3), compensated cirrhosis (Metavir F4) or who are awaiting
liver transplantation initially had access to reimbursement for DAAs by the mandatory health
insurance at the time of their first approval. To address this situation, European countries
implemented different policies.[46] One of them is price negotiation as more than one pharma-
ceutical company enters the hepatitis C market.[43] From August 2015, the Swiss FOPH
extended the use of DAAs to patients with fibrosis stage F2, a lower stage of fibrosis. This
extension was accompanied by a market price reduction. The Tuscany region (Italy) has pro-
posed a more sophisticated tool, i.e., a tendering scheme that extends the accessibility to DAA
for approximately 20,000 patients who have milder disease.[47] As a further example, in the
field of other diseases, Novartis recently declared the launch of their new heart failure drug,
Entresto1 (sacubitril associated to valsartan), offering a high rebate while subsequently
increasing prices if the new drug reduces hospitals visits.[48]
Our study had limitations. First, we included only treatment-naive patients infected with
HCV genotype 1. However, this is the largest subgroup of hepatitis C patients in Switzerland,
and it is sufficiently representative for studying the pricing business model.[25] Moreover,
HCV genotype 1 has been the most difficult genotype to treat for the last two decades, justify-
ing the efforts to develop novel genotype-specific drugs. Second, prices are negotiated over
time, and the market price at the time of licensing may not necessarily reflect the future, evolv-
ing situation.
In conclusion, there is a relatively stable ratio of costs per cured patient over time, resulting
in a strong positive correlation between the HCV cure rate and costs per treatment. This is an
indication that pharmaceutical companies used a value-based pricing model for HCV treat-
ments. The finding is in line with a claim by Ezekiel J. Emanuel, who stated that high HCV
prices are not fully accounted by high costs of R&D or risks associated with drug development.
[49] Health care systems, even of wealthy countries, such as Switzerland and the US, are strug-
gling with the high budget impact of these new agents. Ironically, the issue is caused by the
very high effectiveness of the DAAs and the willingness to pay for a specific health gain (i.e.
one SVR) set 25 years ago, with the consequence of high prices due to the high patient value.
Nevertheless, the current pricing of antiviral drugs against HCV does not allow treatment of all
HCV-infected patients despite the obvious long-term advantages in terms of population health.
Therefore, the pharmaceutical industry, health care payers and stakeholders are challenged
with finding new pricing schemes to treat the entire population for new drugs that are highly
effective when the disease prevalence is high.
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